SavedAdd your journal

Journals / Medical Science and Discovery / 2016 / Cilt: 3 Sayı: 3

Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma

Ali ESER
Funda PEPEDİL TANRİKULU
Ayse Tulin FİRATLİ TUGLULAR
Pages
151–2
Publication Date
2016-03-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although possible association between SPMs in patients receiving lenalidomide can be attributed to previous melphalan use, potential SPM risk with lenalidomide cannot still be ruled out safely

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 53-year-old patient who had a 7 year history of multiple myeloma was diagnosed with high risk myelodysplastic syndrome while on lenalidomide treatment.
📊
Key Findings & Data:Progression to acute myeloid leukemia has occurred during the following 4 months.
💡
Conclusion & Impact:Although possible association between SPMs in patients receiving lenalidomide can be attributed to previous melphalan use, potential SPM risk with lenalidomide cannot still be ruled out safely
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Multiple myeloma · Lenalidomide · Acute myeloid leukemia

Abstract

A 53-year-old patient who had a 7 year history of multiple myeloma was diagnosed with high risk myelodysplastic syndrome while on lenalidomide treatment. Progression to acute myeloid leukemia has occurred during the following 4 months. Like our case, secondary primary malignancies (SPMs) can rarely complicate treatment of multiple myeloma. Although possible association between SPMs in patients receiving lenalidomide can be attributed to previous melphalan use, potential SPM risk with lenalidomide cannot still be ruled out safely

🔖

Cite This Article

ESER, A., TANRİKULU, F. P., TUGLULAR, A. T. F. (2016). Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma. Medical Science and Discovery, Cilt: 3 Sayı: 3, 151–2. https://ajindex.com/articles/1003084

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med. 1970;283(21):1121-5.
  2. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-91.
  3. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-81.
  4. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-69.
  5. Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2012;119(12):2764-7.
  6. Rossi AC, Mark TM, Jayabalan D, Christos PJ, Zafar F, Pekle K, et al. Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM). J Clin Oncol. 2011;29: abstr 8008.